Atossa Therapeutics Inc (ATOS): Atossa Therapeutics Receives $21 Milli...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	483
Posts	61598
Boards Moderated	14
Alias Born	09/20/2001

XenaLives

Re: None

Thursday, 07/29/2021 1:40:05 AM

Thursday, July 29, 2021 1:40:05 AM

Atossa Therapeutics Receives $21 Million from Recent Exercises of Outstanding Warrants

SEATTLE, Jan. 29, 2021 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, announced that it has received $21 million from the exercise of outstanding warrants. The warrants were issued in financings in December 2020 and January 2021.

“In the past 60 days, we have made great progress in adding substantial cash resources so that we can accelerate development of our COVID-19 and breast cancer therapies,” commented Kyle Guse, CFO and General Counsel. “We completed financings with gross proceeds of approximately $60 million and in the past week have added an additional $21 million to our balance sheet through the exercise of outstanding warrants. We look forward to the speed at which we can now advance our programs in 2021.”

https://atossatherapeutics.com/atossa-therapeutics-receives-21-million-from-recent-exercises-of-outstanding-warrants/